Lupin-Yoshindo Stake Claim For Play In Japan Biosimilar Enbrel Market

 
• By Anju Ghangurde

Lupin and partner Yoshindo have sought marketing authorization for their biosimilar Enbrel in Japan. While not the first biosimilar etanercept in Japan, the NDA is seen opening up multiple opportunities for Lupin as it transitions to “higher complexity” products.

Leadership
LUPIN-YOSHINDO ARE SEEKING REGULATORY CLEARANCE FOR BIOSIMILAR ENBREL IN JAPAN

More from Business

More from Scrip